In June 2026, China's National Medical Products Administration (NMPA) approved iza-bren (brand name: Yizekang®; generic name: Loncastuximab Eglonatamab), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) independently developed by Biokin Pharmaceutical. The approval is for the treatment of patients with relapsed or metastatic nasopharyngeal carcinoma (NPC) following prior therapy.As the world’s first approved bispecific ADC, iza-bren marks the beginning of a new era in oncology treatment. Chinese patients are also the first globally to gain access to this breakthrough therapeutic modality.
The approval was supported by results from PANKU-NPC 01 (BL-B01D1-303), the world’s first confirmatory Phase III trial evaluating a second-line treatment for recurrent/metastatic NPC. Compared with standard chemotherapy options (gemcitabine, capecitabine, or docetaxel), iza-bren demonstrated substantially superior efficacy:
- Confirmed objective response rate (cORR): 54.6% vs 27.0%
- Median progression-free survival (mPFS): 8.4 months vs 4.3 months
- Median overall survival (mOS): Not yet reached
Based on these compelling clinical outcomes, iza-bren has been incorporated into both the 2026 CSCO Guidelines for Nasopharyngeal Carcinoma and the 2026 NCCN Guidelines for Nasopharyngeal Carcinoma (China Edition) with the highest level of recommendation, fundamentally reshaping the treatment landscape for relapsed/metastatic NPC.
First Approved Bispecific ADC Ushers in a New Global Era
The approval and commercialization of iza-bren represent a landmark technological breakthrough in oncology. The successful transition of the world’s first bispecific ADC from concept to routine clinical practice signals the beginning of the global bispecific ADC era.
China became the first country to successfully translate bispecific ADC technology into clinical application. From early mechanistic studies and proof-of-concept research to pivotal Phase III confirmation trials, the entire development program has remained at the forefront of global innovation.
Because of its earlier approval in China, Chinese patients gain access to this transformative therapy ahead of patients in other regions. This time advantage may translate directly into survival benefits, highlighting the importance of timely access to innovative treatments.
Furthermore, China’s early adoption allows the accumulation of real-world clinical experience, supports expansion into additional tumor indications, and contributes to the development of clinical guidelines and regulatory frameworks for bispecific ADC therapies worldwide.
From Scientific Innovation to Guideline Transformation
Mechanistic Innovation: Dual-Target Synergy to Overcome Resistance
Traditional EGFR-targeted therapies often encounter resistance as tumor cells activate compensatory HER3 signaling pathways. Meanwhile, HER3-targeted monoclonal antibodies have generally shown limited efficacy because HER3 possesses minimal intrinsic kinase activity.
Consequently, single-target approaches have struggled to simultaneously achieve strong efficacy and prevent resistance.
Iza-bren is the world’s first EGFR×HER3 bispecific ADC, designed to address these challenges through several innovative mechanisms:
- Dual-target recognition enhances tumor selectivity and reduces off-target toxicity.
- Simultaneous blockade of EGFR and HER3 signaling pathways interrupts major resistance mechanisms.
- A high drug-to-antibody ratio (DAR ≈ 8) provides potent cytotoxic payload delivery.
- A strong bystander effect enables elimination of neighboring tumor cells, including those with low or absent target expression.
Together, these features allow iza-bren to enhance efficacy while overcoming resistance pathways that limit conventional targeted therapies.
Therapeutic Innovation: Doubling Efficacy Compared with Chemotherapy
Historically, second-line treatment options for recurrent/metastatic NPC have relied primarily on single-agent chemotherapy. Reported objective response rates have generally been around 30%, while median progression-free survival has ranged from approximately 1.5 to 5.3 months. Most supporting evidence has originated from relatively small Phase II studies.
The pivotal BL-B01D1-303 trial, led by Prof. Li Zhang of Sun Yat-sen University Cancer Center and involving 55 centers nationwide, enrolled 386 patients and became the first Phase III confirmatory trial in this setting.
Compared with standard chemotherapy, iza-bren achieved remarkable improvements:
- cORR increased to 54.6%, compared with 27.0% for chemotherapy.
- The odds ratio for response was 3.3.
- Median PFS reached 8.4 months, nearly double the 4.3 months observed with chemotherapy.
- The risk of disease progression or death was reduced by 56% (HR = 0.44), representing one of the largest risk reductions reported in this setting.
Safety was manageable and predictable. Adverse events were primarily hematologic in nature, and only 2.6% of patients discontinued treatment because of treatment-related adverse events, allowing the vast majority to complete therapy.
Changing Clinical Practice and Rewriting Guidelines
Supported by high-level evidence from BL-B01D1-303, iza-bren rapidly gained guideline recognition.
The 2026 CSCO Guidelines for Nasopharyngeal Carcinoma designated iza-bren as the preferred second-line treatment option for recurrent/metastatic NPC, supported by the only Category 1A evidence in this setting.
Similarly, the 2026 NCCN Guidelines for Nasopharyngeal Carcinoma (China Edition) listed iza-bren as the preferred treatment option for recurrent, unresectable, oligometastatic, or metastatic NPC after prior therapy, with unanimous consensus among Chinese guideline panel members.
As a result, iza-bren establishes a new treatment standard and addresses a long-standing unmet need in the management of recurrent/metastatic NPC.
Beyond Nasopharyngeal Carcinoma: Expanding a Global Oncology Platform
As of June 2026, Yizekang® is being evaluated in more than 40 clinical trials across China and the United States, spanning multiple tumor types.
The program has already received:
- Eight Breakthrough Therapy Designations Seven from China’s Center for Drug Evaluation (CDE) One from the U.S. Food and Drug Administration (FDA)
- Two Priority Review Designations from the CDE, including the already approved NPC indication
In China, 15 pivotal Phase II/III PANKU registration studies are underway across a broad range of malignancies, including:
- Lung cancer
- Esophageal squamous cell carcinoma
- Breast cancer
- Ovarian cancer
- Urothelial carcinoma
- Cholangiocarcinoma
Marketing applications for esophageal squamous cell carcinoma and triple-negative breast cancer have already been formally accepted for review.
Globally, three pivotal IZABRIGHT Phase II/III programs are ongoing in lung cancer, triple-negative breast cancer, and urothelial carcinoma.
From becoming the first bispecific ADC to enter Phase III development to becoming the first approved bispecific ADC worldwide, iza-bren is poised to redefine treatment paradigms across multiple cancer types.
Conclusion
The approval of iza-bren represents more than the launch of a new drug—it marks the arrival of a new therapeutic era.
For years, bispecific ADCs existed only within clinical trials. Today, this innovative treatment is available to patients with recurrent or metastatic nasopharyngeal carcinoma in routine clinical practice.
China’s innovation leadership is not only advancing global oncology research but also delivering tangible benefits to patients. The era of bispecific ADC therapy has begun, and Chinese patients are the first to witness—and benefit from—this transformative milestone.
The future is no longer approaching; it has arrived. Through continued innovation, new hope is reaching more patients than ever before.
